During the FDA ODAC (Oncologic Drugs Advisory Committee) meeting on September 26, 2024, the risks and benefits of the treatment with anti-PD-1 antibodies for the first-line treatment of patients with unresectable or metastatic ESCC with PD-L1 expression <1 were discussed. This evidence concerns the gene CD274 and esophageal squamous cell carcinoma.